Hawkhill is developing a first-in-class oral small-molecule therapy for obesity designed to deliver meaningful fat loss while preserving muscle mass, addressing an increasingly recognised limitation of current weight-loss treatments.
Hawkhill is developing a first-in-class oral small-molecule therapy for obesity designed to deliver meaningful fat loss while preserving muscle mass, addressing an increasingly recognised limitation of current weight-loss treatments.
The underlying biology and early asset development were incubated within Tay Therapeutics. The creation of Hawkhill represents the next stage in advancing this science through a dedicated company focused on obesity and metabolic disease.
o2h Ventures has been a long-standing investor in Tay Therapeutics and has worked closely with the founding team over several years as the biology and therapeutic concept have evolved.
| Status | |
| Website | https://hawkhilltherapeutics.com/ |
| Category | Biotech |
| Modality | Small Molecule |
| Therapautics Area | Metabolic health |
| Headquarters | Cambridge, UK |
| Investment Portfolio |